Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (4.599.648 €): EBiSC2 – Eine nachhaltige Europäische Bank für induzierte pluripotente Stammzellen Hor01.03.2019 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
EBiSC2 – Eine nachhaltige Europäische Bank für induzierte pluripotente Stammzellen
EBiSC2 builds on the achievements of the European Bank for iPSCs (EBiSC1) in centralising existing capacities across Europe in a unique banking and distribution infrastructure for research use in response to the increasing demand for human induced pluripotent stem cells (iPSC). Significant progress towards this aim has been made by EBiSC1; further resources, however, are required to ensure self-sustainability. Key partners of EBiSC1 who have delivered major assets of the current bank, join efforts to establish EBiSC2 as self-sustainable, central bank. Based on a gap analysis of the EBiSC1 endeavours towards sustainability, and focussing on user demand, scientific excellence and productivity, EBiSC2 will deploy a business strategy for a sustainable, non-for-profit bank providing access to disease-relevant and quality-controlled iPSCs, along with comprehensive data and freedom to operate for academic and commercial use. To meet evolving requirements from industry and academia, the cell catalogue will be constantly enriched through on-demand generation of new iPSC lines, including gene-edited lines and isogenic controls, iPSC-derived and progenitor cells. EBiSC2 will distribute cell lines and develop a range of additional cell services (incl. screening panels of disease-relevant iPSC and control lines in ready-to-use-formats) to extend its offer, while reducing operational costs through state-of-the-art upscaling and automation enabling bulk production of standardised high-quality cells. Proof-of-concept studies performed jointly by academia and industry will demonstrate the reliability and robustness of the lines for disease modelling and screening and enrich the EBiSC2 catalogue with extensive data. To bundle resources, EBiSC2 focuses on collaboration with iPSC programmes and aims to serve as central hub for EU-funded projects to bank their iPSC lines, and thus, enable long-term access by the research community to the results of European investments.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| ARTTIC INNOVATION GmbH | 148.160 € |
| Arttic | 125.101 € |
| BAYER AG | 0,00 € |
| Bioneer A/S | 374.625 € |
| CHARITE - UNIVERSITAETSMEDIZIN BERLIN | 287.769 € |
| 300.208 € | |
| Eli Lilly and Company Ltd. | 0,00 € |
| FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. | 3.127.209 € |
| Fraunhofer UK Research Ltd. | 0,00 € |
| 0,00 € | |
| H. Lundbeck AS | 0,00 € |
| Institut de Recherches Servier | 0,00 € |
| Janssen Pharmaceutica N.V. | 0,00 € |
| Katholieke Universiteit Leuven | 236.575 € |
| Novo Nordisk A/S | 0,00 € |
| Pfizer Ltd. | 0,00 € |
| TAKEDA PHARMACEUTICALS INTERNATIONAL AG | 0,00 € |
| Takeda Development Centre Europe Ltd. | 0,00 € |
| UCB Biopharma | 0,00 € |
Quelle: https://cordis.europa.eu/project/id/821362
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
Die Visualisierungen zu "ARTTIC INNOVATION GmbH - EU-Förderung (4.599.648 €): EBiSC2 – Eine nachhaltige Europäische Bank für induzierte pluripotente Stammzellen"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
